Irrespective of reaching an entire response with optimum induction therapy, minimal residual condition frequently persists, necessitating consolidation therapy to mitigate the risk of relapse by doing away with residual sickness. In patients who have been given 7+3 induction therapy, consolidation therapy is initiated with significant-dose cytarab